The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Correspondence
PreviousPrevious
Volume 359:970-971 August 28, 2008 Number 9
NextNext

Initial Treatment of HIV-1 Infection

Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

 Sign up for free e-toc
 

This Article
-Full Text
- PDF
-PDA Full Text
-Purchase this article

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited
-E-mail When Letters Appear

More Information
-Related Article
by Hirschel, B.
-Related Article
by Riddler, S. A.
-PubMed Citation
To the Editor: In their study comparing three different regimens for initial treatment of human immunodeficiency virus type 1 (HIV-1) infection, Riddler et al. (May 15 issue)1 state that 19 patients died, but the authors report deaths according to study group only in the Supplementary Appendix. These data indicate that nine patients died in the efavirenz group, seven in the nucleoside reverse-transcriptase inhibitor (NRTI)–sparing group, and three in the lopinavir–ritonavir group, but causes of death are not reported. Neither a pairwise comparison of death in the three study groups nor a comparison between the two groups receiving efavirenz (the efavirenz . . . [Full Text of this Article]



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.